Steven M. Yip

Steven M. Yip

Auto-generated profile, based on publicly available information

Steven M. Yip

Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 2018 in Cancer
Verified
Journal Article
Closed access
PDF file
SYSteven M. Yip
Steven M. Yip
CWConnor Wells
Connor Wells
RMRaphael Moreira
Raphael Moreira
AWAlex Wong
Alex Wong
SSSandy Srinivas
Sandy Srinivas
DHDaniel Y.C. Heng
Daniel Y.C. Heng

10 March 2021 in Cancer
Verified
Journal Article
Closed access
PDF file
DKDaniel H. Kwon
Daniel H. Kwon
JCJonathan Chou
Jonathan Chou
SYSteven M. Yip
Steven M. Yip
MRMelissa A. Reimers
Melissa A. Reimers
LZLi Zhang
Li Zhang
VKVadim S Koshkin
Vadim S Koshkin

20 February 2022 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
LLLuke Lavallee
Luke Lavallee
CMChris Morash
Chris Morash
Fred SaadFred Saad
Fred Saad
SYSteven Yip
Steven Yip
Anil KapoorAnil Kapoor
Anil Kapoor
Tamim NiaziTamim Niazi
Tamim Niazi
252 Background: The management of patients with mCRPC has evolved since the introduction of androgen-receptor axis targeted agents (ARATs). The Genitourinary Research Consortium (GURC) initiated a prospective, phase 4, multicentre, non-interventional, longitudinal cohort study of Canadian men with advanced prostate cancer to determine real-world treatment patterns and outcomes. Methods: 25 sites across Canada participated in this study including patients managed by urologists, medical- and radiation-oncologists between 2018 to 2021. Baseline patient characteristics and mCRPC treatment patterns are reported here. Treatment patterns reviewed included time to second-line treatment use and time to progression or death. Results: 136 mCRPC patients were enrolled. Median age was 73 years (range 66 to 80) with 54 (40%) having a Gleason score of >8 at diagnosis. Median PSA at enrollment was 8.9 (2.4 to 25.1) ng/ml. At study entry, 90/132 (66%) patients with mCSPC and 42/132 (31%) patients nmCRPC had progressed to develop mCRPC. One hundred and twenty-one (89%) of patients in this cohort received first-line treatment for mCRPC, the most common was abiraterone acetate + prednisone in 67 (49%) and enzalutamide in 41 (30%), followed by docetaxel in 6 (4.4%), and Radium-223 in 5 (3.7%) patients. During the 25-month median follow-up period (range 6-28), 59 (49%) of the patients receiving first line mCRPC therapy had documented disease progression or death. At the time of last recorded follow-up, 37 (28%) patients who progressed received a second-line therapy for mCRPC. Median time to progression in this cohort was 21 months (95% CI: 15.2 - NE), with ARAT-to-ARAT being the most common sequencing pattern observed in 15 (39%) patients, followed by ARAT to chemotherapy in 14 (37%). Conclusions: In this real-world analysis of mCRPC patients, ARAT therapy was the preferred approach for first-line treatment intensification in over 108 (80%) patients. Despite evidence of poor response rates, ARAT-to-ARAT was the most common sequencing for second line therapy, followed by ARAT-to-chemotherapy treatment. Further analysis and follow-up will help define optimal mCRPC management, in real world setting.